{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:07:13Z","timestamp":1792260433528,"version":"4.4.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","award":["ARUK-SRF2022A-006"],"award-info":[{"award-number":["ARUK-SRF2022A-006"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dementia with Lewy bodies (DLB) is thought to be the second most common form of dementia after Alzheimer\u2019s disease, and is characterised by a combination of cognitive, neuropsychiatric and motor symptoms. The present review seeks to discuss current strategies for the management of DLB, and future directions for novel disease-modifying therapies. Current best practice for the clinical management of DLB is based upon therapies that target specific symptom domains due to the lack of disease-modifying therapies. Cholinesterase inhibitors are the frontline treatment for treating cognitive decline in DLB, whereas the treatment of motor symptoms remains challenging due to poor response to dopaminergic therapies and the potential for exacerbation of neuropsychiatric features. There is emerging evidence suggesting a range of further pharmacological and non-pharmacological therapies may be effective in treating specific symptom domains of DLB, but further evidence is warranted to demonstrate their efficacy. A key challenge in the treatment of DLB is incomplete understanding of disease pathophysiology, which has limited attempts to develop disease-modifying therapies. In the present article, we discuss the multi-faceted nature of DLB neuropathology, from Lewy body pathology to mitochondrial dysfunction, and discuss therapies in development that target particular aspects of DLB neuropathology. In particular, we highlight antibody-based therapies to attenuate protein aggregation, compounds that enhance the generation of cellular energy and autophagy-enhancing agents as particular areas of promise. Furthermore, we discuss how optimal strategies for disease modification will be centred on agents that treat DLB neuropathology more holistically, and will be underpinned by a more complete understanding of the pathogenic events that underlie the full spectrum of pathological changes observed in the DLB brain.<\/jats:p>","DOI":"10.1186\/s13024-025-00856-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:57:03Z","timestamp":1751363823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology"],"prefix":"10.1186","volume":"20","author":[{"given":"Daniel","family":"Erskine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Paul","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"1","key":"856_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, et al. Dementia with lewy bodies: an update and outlook. Mol Neurodegener. 2019;14(1):5.","journal-title":"Mol Neurodegener"},{"issue":"1","key":"856_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"4","key":"856_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2014","unstructured":"Vann Jones SA, O\u2019Brien JT. The prevalence and incidence of dementia with lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2014;44(4):673\u201383.","journal-title":"Psychol Med"},{"key":"856_CR4","volume-title":"Diagnostic performance and clinical applications of a commercial Alpha-synuclein seed amplification assay in a tertiary care memory clinic (S1. 010)","year":"2024","unstructured":"Porter A, Christian L, Tipton P, Graff-Radford N, Day G, editors. Diagnostic performance and clinical applications of a commercial Alpha-synuclein seed amplification assay in a tertiary care memory clinic (S1. 010). Neurology: AAN Enterprises. 2024."},{"issue":"Pt 3","key":"856_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/brain\/awh725","volume":"129","author":"P Tiraboschi","year":"2006","unstructured":"Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates lewy body from alzheimer\u2019s disease in early-stage dementia? Brain. 2006;129(Pt 3):729\u201335.","journal-title":"Brain"},{"issue":"4","key":"856_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3233\/JPD-230001","volume":"13","author":"TD Fedorova","year":"2023","unstructured":"Fedorova TD, Knudsen K, Horsager J, Hansen AK, Okkels N, Gottrup H, et al. Dopaminergic dysfunction is more symmetric in dementia with lewy bodies compared to parkinson\u2019s disease. J Parkinsons Dis. 2023;13(4):515\u201323.","journal-title":"J Parkinsons Dis"},{"issue":"15","key":"856_CR7","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/mds.22322","volume":"23","author":"JG Goldman","year":"2008","unstructured":"Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with lewy bodies. Mov Disord. 2008;23(15):2248\u201350.","journal-title":"Mov Disord"},{"issue":"17","key":"856_CR8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with lewy bodies. Neurology. 2020;94(17):743\u201355.","journal-title":"Neurology"},{"key":"856_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0350-6","volume":"10","author":"JP Kane","year":"2018","unstructured":"Kane JP, Surendranathan A, Bentley A, Barker SA, Taylor J-P, Thomas AJ, et al. Clinical prevalence of lewy body dementia. Alzheimers Res Ther. 2018;10:1\u20138.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"856_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/pgfar09070","volume":"9","author":"JT O\u2019Brien","year":"2021","unstructured":"O\u2019Brien JT, Taylor J-P, Thomas A, Bamford C, Vale L, Hill S, et al. Improving the diagnosis and management of lewy body dementia: the DIAMOND-Lewy research programme including pilot cluster RCT. Programme Grants Appl Res. 2021;9(7):1\u2013120.","journal-title":"Programme Grants Appl Res"},{"key":"856_CR11","doi-asserted-by":"publisher","first-page":"105807","DOI":"10.1016\/j.parkreldis.2023.105807","volume":"117","author":"BF Gomes","year":"2023","unstructured":"Gomes BF, Farris CM, Ma Y, Concha-Marambio L, Lebovitz R, Nellg\u00e5rd B, et al. \u03b1-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. Parkinsonism Relat Disord. 2023;117:105807.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"856_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU Hoglinger","year":"2024","unstructured":"Hoglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, et al. A biological classification of parkinson\u2019s disease: the synneurge research diagnostic criteria. Lancet Neurol. 2024;23(2):191\u2013204.","journal-title":"Lancet Neurol"},{"issue":"2","key":"856_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, et al. A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178\u201390.","journal-title":"Lancet Neurol"},{"key":"856_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1385\/JMN:17:2:225","volume":"17","author":"PT Kotzbauer","year":"2001","unstructured":"Kotzbauer PT, Trojanowski JQ, Lee VM-Y. Lewy body pathology in alzheimer\u2019s disease. J Mol Neurosci. 2001;17:225\u201332.","journal-title":"J Mol Neurosci"},{"issue":"10","key":"856_CR15","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1002\/mds.30007","volume":"39","author":"LV Kalia","year":"2024","unstructured":"Kalia LV, Berg D, Kordower JH, Shannon KM, Taylor JP, Cardoso F, et al. International Parkinson and movement disorder society viewpoint on biological frameworks of Parkinson\u2019s disease: current status and future directions. Mov Disord. 2024;39(10):1710\u20135.","journal-title":"Mov Disord"},{"key":"856_CR16","doi-asserted-by":"crossref","unstructured":"Ghanem S, Hawksworth J, Thom S, Hartanto AE, O\u2019Neill J, Ponraj J et al. Seed-competent alpha-synuclein pathology in metachromatic leukodystrophy: the expanding spectrum of alpha-synucleinopathy in sphingolipidoses. BioRxiv. 2024;2024.08.09.607301.","DOI":"10.1101\/2024.08.09.607301"},{"issue":"4","key":"856_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/brain\/awac002","volume":"145","author":"C Hatton","year":"2022","unstructured":"Hatton C, Ghanem SS, Koss DJ, Abdi IY, Gibbons E, Guerreiro R, et al. Prion-like alpha-synuclein pathology in the brain of infants with Krabbe disease. Brain. 2022;145(4):1257\u201363.","journal-title":"Brain"},{"issue":"3","key":"856_CR18","doi-asserted-by":"publisher","first-page":"e209656","DOI":"10.1212\/WNL.0000000000209656","volume":"103","author":"DG Coughlin","year":"2024","unstructured":"Coughlin DG, MacLeod KR, Middleton JS, Bozoki AC, Galvin JE, Irwin DJ, et al. Association of CSF \u03b1-Synuclein seeding amplification assay results with clinical features of possible and probable dementia with lewy bodies. Neurology. 2024;103(3):e209656.","journal-title":"Neurology"},{"issue":"1","key":"856_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40478-022-01388-7","volume":"10","author":"S Hall","year":"2022","unstructured":"Hall S, Orr\u00f9 CD, Serrano GE, Galasko D, Hughson AG, Groveman BR, et al. Performance of \u03b1Synuclein RT-QuIC in relation to neuropathological staging of lewy body disease. Acta Neuropathol Commun. 2022;10(1):90.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"856_CR20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"J-P Taylor","year":"2020","unstructured":"Taylor J-P, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of lewy body dementia. Lancet Neurol. 2020;19(2):157\u201369.","journal-title":"Lancet Neurol"},{"key":"856_CR21","doi-asserted-by":"publisher","first-page":"102604","DOI":"10.1016\/j.nicl.2021.102604","volume":"30","author":"J Schumacher","year":"2021","unstructured":"Schumacher J, Taylor JP, Hamilton CA, Firbank M, Cromarty RA, Donaghy PC, et al. In vivo nucleus basalis of meynert degeneration in mild cognitive impairment with lewy bodies. Neuroimage Clin. 2021;30:102604.","journal-title":"Neuroimage Clin"},{"issue":"1","key":"856_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40478-020-00985-8","volume":"8","author":"C Hatton","year":"2020","unstructured":"Hatton C, Reeve A, Lax NZ, Blain A, Ng YS, El-Agnaf O, et al. Complex I reductions in the nucleus basalis of meynert in lewy body dementia: the role of lewy bodies. Acta Neuropathol Commun. 2020;8(1):103.","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"856_CR23","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/NEN.0000000000000014","volume":"72","author":"DH Hepp","year":"2013","unstructured":"Hepp DH, Ruiter AM, Galis Y, Voorn P, Rozemuller AJ, Berendse HW, et al. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with lewy bodies patients. J Neuropathol Exp Neurol. 2013;72(12):1162\u201370.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"856_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13195-014-0081-2","volume":"7","author":"E Mori","year":"2015","unstructured":"Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with lewy bodies: results from an open-label extension of phase III trial. Alzheimers Res Ther. 2015;7(1):5.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"856_CR25","first-page":"CD003672","volume":"2003","author":"R Wild","year":"2003","unstructured":"Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with lewy bodies. Cochrane Database Syst Rev. 2003;2003(3):CD003672.","journal-title":"Cochrane Database Syst Rev"},{"key":"856_CR26","doi-asserted-by":"crossref","unstructured":"Xu H, Habich A, Ferreira D, Elisabet L, Westman E, Eriksdotter M. Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with lewy bodies: an up to 10\u2010year follow\u2010up study. Alzheimer\u2019s & Dementia. 2024.","DOI":"10.1002\/alz.14118"},{"key":"856_CR27","doi-asserted-by":"publisher","first-page":"109737","DOI":"10.1016\/j.neuropharm.2023.109737","volume":"244","author":"PK Tari","year":"2024","unstructured":"Tari PK, Parsons CG, Collingridge GL, Rammes G. Memantine: updating a rare success story in pro-cognitive therapeutics. Neuropharmacology. 2024;244:109737.","journal-title":"Neuropharmacology"},{"issue":"5","key":"856_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1007\/s10439-011-0494-z","volume":"40","author":"MK Kutzing","year":"2012","unstructured":"Kutzing MK, Luo V, Firestein BL. Protection from glutamate-induced excitotoxicity by memantine. Ann Biomed Eng. 2012;40(5):1170\u201381.","journal-title":"Ann Biomed Eng"},{"issue":"4","key":"856_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jagp.2013.11.007","volume":"23","author":"S Matsunaga","year":"2015","unstructured":"Matsunaga S, Kishi T, Iwata N. Memantine for lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psychiatry. 2015;23(4):373\u201383.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"856_CR30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, Dest\u00e9e A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with parkinson\u2019s disease dementia or dementia with lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377.","journal-title":"Lancet Neurol"},{"key":"856_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt251","volume":"6","author":"YR Zweig","year":"2014","unstructured":"Zweig YR, Galvin JE. Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Ther. 2014;6:1\u20137.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"856_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mdc3.12383","volume":"4","author":"MJ Armstrong","year":"2017","unstructured":"Armstrong MJ, Weintraub D. The case for antipsychotics in dementia with lewy bodies. Mov Disorders Clin Pract. 2017;4(1):32.","journal-title":"Mov Disorders Clin Pract"},{"issue":"1","key":"856_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mdc3.12383","volume":"4","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Weintraub D. The case for antipsychotics in dementia with lewy bodies. Mov Disorders Clin Pract. 2016;4(1):32.","journal-title":"Mov Disorders Clin Pract"},{"key":"856_CR34","doi-asserted-by":"publisher","unstructured":"Sugawara Kikuchi Y, Shimizu T. Aripiprazole for the treatment of psychotic symptoms in patients with dementia with lewy bodies: a case series. Neuropsychiatr Dis Treat. 2019: 15:543\u20137. https:\/\/doi.org\/10.2147\/NDT.S189050","DOI":"10.2147\/NDT.S189050"},{"key":"856_CR35","doi-asserted-by":"crossref","unstructured":"Boylan L, Hirsch S. Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia. BMJ Case Rep. 2009;2009.","DOI":"10.1136\/bcr.06.2008.0205"},{"key":"856_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.parkreldis.2019.11.009","volume":"69","author":"S Horn","year":"2019","unstructured":"Horn S, Richardson H, Xie SX, Weintraub D, Dahodwala N. Pimavanserin versus quetiapine for the treatment of psychosis in parkinson\u2019s disease and dementia with lewy bodies. Parkinsonism Relat Disord. 2019;69:119\u201324.","journal-title":"Parkinsonism Relat Disord"},{"key":"856_CR37","doi-asserted-by":"publisher","first-page":"e939806","DOI":"10.12659\/AJCR.939806","volume":"24","author":"KG Rothenberg","year":"2023","unstructured":"Rothenberg KG, McRae SG, Dominguez-Colman LM, Shutes-David A, Tsuang DW. Pimavanserin treatment for psychosis in patients with dementia with lewy bodies: A case series. Am J Case Rep. 2023;24:e939806\u20131.","journal-title":"Am J Case Rep"},{"issue":"6","key":"856_CR38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/gps.5494","volume":"36","author":"MG Borda","year":"2021","unstructured":"Borda MG, Jaramillo-Jimenez A, Oesterhus R, Santacruz JM, Tovar\u2010Rios DA, Soennesyn H, et al. Benzodiazepines and antidepressants: effects on cognitive and functional decline in alzheimer\u2019s disease and lewy body dementia. Int J Geriatr Psychiatry. 2021;36(6):917\u201325.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"856_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/mds.28282","volume":"36","author":"JT O\u2019Brien","year":"2021","unstructured":"O\u2019Brien JT, McKeith IG, Thomas AJ, Bamford C, Vale L, Hill S, et al. Introduction of a management toolkit for lewy body dementia: A pilot Cluster-Randomized trial. Mov Disord. 2021;36(1):143\u201351.","journal-title":"Mov Disord"},{"issue":"2","key":"856_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/13607863.2022.2032601","volume":"27","author":"KE Watts","year":"2023","unstructured":"Watts KE, Storr NJ, Barr PG, Rajkumar AP. Systematic review of Pharmacological interventions for people with lewy body dementia. Aging Ment Health. 2023;27(2):203\u201316.","journal-title":"Aging Ment Health"},{"issue":"1","key":"856_CR41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.64719\/pb.4345","volume":"46","author":"RM Nevels","year":"2016","unstructured":"Nevels RM, Gontkovsky ST, Williams BE. Paroxetine\u2014the antidepressant from hell? Probably not, but caution required. Psychopharmacol Bull. 2016;46(1):77.","journal-title":"Psychopharmacol Bull"},{"issue":"9","key":"856_CR42","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/jnnp.2004.052332","volume":"76","author":"S Molloy","year":"2005","unstructured":"Molloy S, McKeith I, O\u2019brien J, Burn D. The role of Levodopa in the management of dementia with lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"856_CR43","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.parkreldis.2010.06.004","volume":"16","author":"C Lucetti","year":"2010","unstructured":"Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F, et al. Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010;16(8):522\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"856_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","volume":"36","author":"LA Hershey","year":"2019","unstructured":"Hershey LA, Coleman-Jackson R. Pharmacological management of dementia with lewy bodies. Drugs Aging. 2019;36:309\u201319.","journal-title":"Drugs Aging"},{"issue":"8","key":"856_CR45","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","volume":"90","author":"M Murata","year":"2018","unstructured":"Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M, et al. Adjunct Zonisamide to Levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology. 2018;90(8):e664\u201372.","journal-title":"Neurology"},{"key":"856_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.parkreldis.2019.12.005","volume":"76","author":"M Murata","year":"2020","unstructured":"Murata M, Odawara T, Hasegawa K, Kajiwara R, Takeuchi H, Tagawa M, et al. Effect of Zonisamide on parkinsonism in patients with dementia with lewy bodies: a phase 3 randomized clinical trial. Parkinsonism Relat Disord. 2020;76:91\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"856_CR47","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1002\/pcn5.129","volume":"2","author":"K Mizukami","year":"2023","unstructured":"Mizukami K. Autonomic dysfunction in dementia with lewy bodies: focusing on cardiovascular and respiratory dysfunction. Psychiatry Clin Neurosciences Rep. 2023;2(3):e129.","journal-title":"Psychiatry Clin Neurosciences Rep"},{"issue":"1","key":"856_CR48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000529256","volume":"52","author":"L Guidi","year":"2023","unstructured":"Guidi L, Evangelisti S, Siniscalco A, Lodi R, Tonon C, Mitolo M. Non-pharmacological treatments in lewy body disease: a systematic review. Dement Geriatr Cogn Disord. 2023;52(1):16\u201331.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"11","key":"856_CR49","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1017\/S0033291717003257","volume":"48","author":"MH Connors","year":"2018","unstructured":"Connors MH, Quinto L, McKeith I, Brodaty H, Allan L, Bamford C, et al. Non-pharmacological interventions for lewy body dementia: a systematic review. Psychol Med. 2018;48(11):1749\u201358.","journal-title":"Psychol Med"},{"key":"856_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-014-0074-1","volume":"6","author":"GJ Elder","year":"2014","unstructured":"Elder GJ, Taylor J-P. Transcranial magnetic stimulation and transcranial direct current stimulation: treatments for cognitive and neuropsychiatric symptoms in the neurodegenerative dementias? Alzheimers Res Ther. 2014;6:1\u201311.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"856_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1479-8301.2009.00292.x","volume":"9","author":"S Takahashi","year":"2009","unstructured":"Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics. 2009;9(2):56\u201361.","journal-title":"Psychogeriatrics"},{"issue":"2","key":"856_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1017\/S1041610215001180","volume":"28","author":"GJ Elder","year":"2016","unstructured":"Elder GJ, Firbank MJ, Kumar H, Chatterjee P, Chakraborty T, Dutt A, et al. Effects of transcranial direct current stimulation upon attention and visuoperceptual function in lewy body dementia: a preliminary study. Int Psychogeriatr. 2016;28(2):341\u20137.","journal-title":"Int Psychogeriatr"},{"key":"856_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0465-9","volume":"11","author":"GJ Elder","year":"2019","unstructured":"Elder GJ, Colloby SJ, Firbank MJ, McKeith IG, Taylor J-P. Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in lewy body dementia: a randomised controlled trial. Alzheimers Res Ther. 2019;11:1\u201313.","journal-title":"Alzheimers Res Ther"},{"key":"856_CR54","first-page":"e66","volume":"28","author":"Y Yamaguchi","year":"2016","unstructured":"Yamaguchi Y, Matsuoka K, Ueda J, Takada R, Takahashi M, Kiuchi K, et al. The effect of electroconvulsive therapy on psychiatric symptoms of dementia with lewy bodies. J Neuropsychiatry Clin Neurosci. 2016;28:e66.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"12","key":"856_CR55","doi-asserted-by":"publisher","first-page":"e70020","DOI":"10.1002\/gps.70020","volume":"39","author":"F Morikawa","year":"2024","unstructured":"Morikawa F, Kobayashi R, Murayama T, Fukuya S, Tabata K, Fujishiro H, et al. Evaluating electroconvulsive therapy for dementia with lewy bodies, including the prodromal stage: A retrospective study on safety and efficacy. Int J Geriatr Psychiatry. 2024;39(12):e70020.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"856_CR56","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.brs.2020.04.010","volume":"13","author":"J Gratwicke","year":"2020","unstructured":"Gratwicke J, Zrinzo L, Kahan J, Peters A, Brechany U, McNichol A, et al. Bilateral nucleus basalis of meynert deep brain stimulation for dementia with lewy bodies: a randomised clinical trial. Brain Stimul. 2020;13(4):1031\u20139.","journal-title":"Brain Stimul"},{"issue":"Suppl 1Suppl 1","key":"856_CR57","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.parkreldis.2015.09.007","volume":"22","author":"T Konno","year":"2016","unstructured":"Konno T, Ross OA, Puschmann A, Dickson DW, Wszolek ZK. Autosomal dominant parkinson\u2019s disease caused by SNCA duplications. Parkinsonism Relat Disord. 2016;22(Suppl 1Suppl 1):S1\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"856_CR58","first-page":"4318416","volume":"2017","author":"C Campelo","year":"2017","unstructured":"Campelo C, Silva RH. Genetic variants in SNCA and the risk of sporadic parkinson\u2019s disease and clinical outcomes: A review. Parkinsons Dis. 2017;2017:4318416.","journal-title":"Parkinsons Dis"},{"issue":"6354","key":"856_CR59","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal S, Bjornevik K, Im DS, Flierl A, Dong X, Locascio JJ, et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of parkinson\u2019s disease. Science. 2017;357(6354):891\u20138.","journal-title":"Science"},{"issue":"6645","key":"856_CR60","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature"},{"issue":"3","key":"856_CR61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3233\/JPD-2011-11046","volume":"1","author":"L Parkkinen","year":"2011","unstructured":"Parkkinen L, O\u2019Sullivan SS, Collins C, Petrie A, Holton JL, Revesz T, et al. Disentangling the relationship between lewy bodies and nigral neuronal loss in parkinson\u2019s disease. J Parkinsons Dis. 2011;1(3):277\u201386.","journal-title":"J Parkinsons Dis"},{"issue":"6","key":"856_CR62","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1212\/WNL.53.6.1284","volume":"53","author":"E Gomez-Tortosa","year":"1999","unstructured":"Gomez-Tortosa E, Newell K, Irizarry M, Albert M, Growdon J, Hyman BT. Clinical and quantitative pathologic correlates of dementia with lewy bodies. Neurology. 1999;53(6):1284.","journal-title":"Neurology"},{"issue":"3","key":"856_CR63","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/mds.26887","volume":"32","author":"D Erskine","year":"2017","unstructured":"Erskine D, Thomas AJ, Attems J, Taylor JP, McKeith IG, Morris CM, et al. Specific patterns of neuronal loss in the pulvinar nucleus in dementia with lewy bodies. Mov Disord. 2017;32(3):414\u201322.","journal-title":"Mov Disord"},{"issue":"1","key":"856_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1440-1789.2010.01117.x","volume":"31","author":"HG Bernstein","year":"2011","unstructured":"Bernstein HG, Johnson M, Perry RH, LeBeau FE, Dobrowolny H, Bogerts B, et al. Partial loss of parvalbumin-containing hippocampal interneurons in dementia with lewy bodies. Neuropathology. 2011;31(1):1\u201310.","journal-title":"Neuropathology"},{"key":"856_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-016-0334-3","volume":"4","author":"AA Khundakar","year":"2016","unstructured":"Khundakar AA, Hanson PS, Erskine D, Lax NZ, Roscamp J, Karyka E, et al. Analysis of primary visual cortex in dementia with lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. Acta Neuropathol Commun. 2016;4:1\u201318.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"856_CR66","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/ana.26542","volume":"93","author":"WRW Martin","year":"2023","unstructured":"Martin WRW, Younce JR, Campbell MC, Racette BA, Norris SA, Ushe M, et al. Neocortical lewy body pathology parallels parkinson\u2019s dementia, but not always. Ann Neurol. 2023;93(1):184\u201395.","journal-title":"Ann Neurol"},{"issue":"6","key":"856_CR67","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/brain\/awv040","volume":"138","author":"RF Roberts","year":"2015","unstructured":"Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in parkinson\u2019s disease brain. Brain. 2015;138(6):1642\u201357.","journal-title":"Brain"},{"issue":"1","key":"856_CR68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s40478-022-01440-6","volume":"10","author":"H Sekiya","year":"2022","unstructured":"Sekiya H, Tsuji A, Hashimoto Y, Takata M, Koga S, Nishida K, et al. Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in parkinson\u2019s disease. Acta Neuropathol Commun. 2022;10(1):133.","journal-title":"Acta Neuropathol Commun"},{"key":"856_CR69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.neuroscience.2011.10.042","volume":"200","author":"G Muntan\u00e9","year":"2012","unstructured":"Muntan\u00e9 G, Ferrer I, Martinez-Vicente M. \u03b1-synuclein phosphorylation and Truncation are normal events in the adult human brain. Neuroscience. 2012;200:106\u201319.","journal-title":"Neuroscience"},{"issue":"1","key":"856_CR70","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41531-023-00444-w","volume":"9","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam N, Jin S-X, Moors TE, Fonseca-Ornelas L, Shimanaka K, Lei S, et al. Dynamic physiological \u03b1-synuclein S129 phosphorylation is driven by neuronal activity. Npj Parkinson\u2019s Disease. 2023;9(1):4.","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"15","key":"856_CR71","doi-asserted-by":"publisher","first-page":"e2109617119","DOI":"10.1073\/pnas.2109617119","volume":"119","author":"SS Ghanem","year":"2022","unstructured":"Ghanem SS, Majbour NK, Vaikath NN, Ardah MT, Erskine D, Jensen NM, et al. \u03b1-Synuclein phosphorylation at Serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc Natl Acad Sci. 2022;119(15):e2109617119.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"856_CR72","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41593-022-01239-7","volume":"26","author":"S Zhang","year":"2023","unstructured":"Zhang S, Zhu R, Pan B, Xu H, Olufemi MF, Gathagan RJ, et al. Post-translational modifications of soluble \u03b1-synuclein regulate the amplification of pathological \u03b1-synuclein. Nat Neurosci. 2023;26(2):213\u201325.","journal-title":"Nat Neurosci"},{"issue":"3","key":"856_CR73","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","volume":"53","author":"R Chia","year":"2021","unstructured":"Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, et al. Genome sequencing analysis identifies new loci associated with lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021;53(3):294\u2013303.","journal-title":"Nat Genet"},{"issue":"1","key":"856_CR74","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017;16(1):55\u201365.","journal-title":"Lancet Neurol"},{"issue":"5","key":"856_CR75","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.14698","volume":"150","author":"L Walker","year":"2019","unstructured":"Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between parkinson\u2019s disease, parkinson\u2019s disease dementia and dementia with lewy bodies - current issues and future directions. J Neurochem. 2019;150(5):467\u201374.","journal-title":"J Neurochem"},{"issue":"10","key":"856_CR76","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1093\/brain\/awab218","volume":"144","author":"J Schumacher","year":"2021","unstructured":"Schumacher J, Gunter JL, Przybelski SA, Jones DT, Graff-Radford J, Savica R, et al. Dementia with lewy bodies: association of alzheimer pathology with functional connectivity networks. Brain. 2021;144(10):3212\u201325.","journal-title":"Brain"},{"key":"856_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging\u2013Alzheimer\u2019s association guidelines for the neuropathologic assessment of alzheimer\u2019s disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"856_CR78","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/alz.12814","volume":"19","author":"JB Toledo","year":"2023","unstructured":"Toledo JB, Abdelnour C, Weil RS, Ferreira D, Rodriguez-Porcel F, Pilotto A, et al. Dementia with lewy bodies: impact of co\u2010pathologies and implications for clinical trial design. Alzheimer\u2019s Dement. 2023;19(1):318\u201332.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"2","key":"856_CR79","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/archneurol.2007.56","volume":"65","author":"C Soto","year":"2008","unstructured":"Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol. 2008;65(2):184\u20139.","journal-title":"Arch Neurol"},{"issue":"7","key":"856_CR80","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1083\/jcb.143.7.1883","volume":"143","author":"JA Johnston","year":"1998","unstructured":"Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 1998;143(7):1883\u201398.","journal-title":"J Cell Biol"},{"issue":"2","key":"856_CR81","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","volume":"85","author":"AM Pickrell","year":"2015","unstructured":"Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in parkinson\u2019s disease. Neuron. 2015;85(2):257\u201373.","journal-title":"Neuron"},{"issue":"1","key":"856_CR82","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jagp.2019.06.007","volume":"28","author":"AP Rajkumar","year":"2020","unstructured":"Rajkumar AP, Bidkhori G, Shoaie S, Clarke E, Morrin H, Hye A, et al. Postmortem cortical transcriptomics of lewy body dementia reveal mitochondrial dysfunction and lack of neuroinflammation. Am J Geriatr Psychiatry. 2020;28(1):75\u201386.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"856_CR83","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/archneurol.2011.2675","volume":"69","author":"AK Reeve","year":"2012","unstructured":"Reeve AK, Park TK, Jaros E, Campbell GR, Lax NZ, Hepplewhite PD, et al. Relationship between mitochondria and alpha-synuclein: a study of single substantia Nigra neurons. Arch Neurol. 2012;69(3):385\u201393.","journal-title":"Arch Neurol"},{"issue":"1","key":"856_CR84","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00401-019-02105-w","volume":"139","author":"D Erskine","year":"2020","unstructured":"Erskine D, Reeve AK, Polvikoski T, Schaefer AM, Taylor RW, Lax NZ, et al. Lewy body pathology is more prevalent in older individuals with mitochondrial disease than controls. Acta Neuropathol. 2020;139(1):219\u201321.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"856_CR85","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/brain\/awab353","volume":"145","author":"YS Ng","year":"2022","unstructured":"Ng YS, Lax NZ, Blain AP, Erskine D, Baker MR, Polvikoski T, et al. Forecasting stroke-like episodes and outcomes in mitochondrial disease. Brain. 2022;145(2):542\u201354.","journal-title":"Brain"},{"issue":"1","key":"856_CR86","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00401-017-1787-6","volume":"135","author":"D Erskine","year":"2018","unstructured":"Erskine D, Patterson L, Alexandris A, Hanson PS, McKeith IG, Attems J, et al. Regional levels of physiological alpha-synuclein are directly associated with lewy body pathology. Acta Neuropathol. 2018;135(1):153\u20134.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"856_CR87","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann MHR, Angelova PR, Horrocks MH, Choi ML, Rodrigues M, Baev AY, et al. alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in parkinson\u2019s disease. Nat Commun. 2018;9(1):2293.","journal-title":"Nat Commun"},{"issue":"9","key":"856_CR88","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41593-022-01140-3","volume":"25","author":"ML Choi","year":"2022","unstructured":"Choi ML, Chappard A, Singh BP, Maclachlan C, Rodrigues M, Fedotova EI, et al. Pathological structural conversion of alpha-synuclein at the mitochondria induces neuronal toxicity. Nat Neurosci. 2022;25(9):1134\u201348.","journal-title":"Nat Neurosci"},{"key":"856_CR89","doi-asserted-by":"publisher","first-page":"105698","DOI":"10.1016\/j.nbd.2022.105698","volume":"168","author":"J Amin","year":"2022","unstructured":"Amin J, Erskine D, Donaghy PC, Surendranathan A, Swann P, Kunicki AP, et al. Inflammation in dementia with lewy bodies. Neurobiol Dis. 2022;168:105698.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"856_CR90","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp-2017-317134","volume":"89","author":"E King","year":"2018","unstructured":"King E, O\u2019Brien JT, Donaghy P, Morris C, Barnett N, Olsen K, et al. Peripheral inflammation in prodromal alzheimer\u2019s and lewy body dementias. J Neurol Neurosurg Psychiatry. 2018;89(4):339\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"856_CR91","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41398-020-00954-8","volume":"10","author":"J Amin","year":"2020","unstructured":"Amin J, Holmes C, Dorey RB, Tommasino E, Casal YR, Williams DM, et al. Neuroinflammation in dementia with lewy bodies: a human post-mortem study. Transl Psychiatry. 2020;10(1):267.","journal-title":"Transl Psychiatry"},{"key":"856_CR92","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00702-017-1726-7","volume":"124","author":"JJ Tomlinson","year":"2017","unstructured":"Tomlinson JJ, Shutinoski B, Dong L, Meng F, Elleithy D, Lengacher NA, et al. Holocranohistochemistry enables the visualization of \u03b1-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. J Neural Transm. 2017;124:721\u201338.","journal-title":"J Neural Transm"},{"issue":"5","key":"856_CR93","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1159\/000479653","volume":"9","author":"V Labrie","year":"2017","unstructured":"Labrie V, Brundin P. Alpha-synuclein to the rescue: immune cell recruitment by alpha-synuclein during Gastrointestinal infection. J Innate Immun. 2017;9(5):437\u201340.","journal-title":"J Innate Immun"},{"key":"856_CR94","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/bs.pmbts.2019.06.002","volume":"168","author":"CT Tulisiak","year":"2019","unstructured":"Tulisiak CT, Mercado G, Peelaerts W, Brundin L, Brundin P. Can infections trigger alpha-synucleinopathies? Prog Mol Biol Transl Sci. 2019;168:299\u2013322.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"9","key":"856_CR95","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/15548627.2015.1067364","volume":"11","author":"Z Gan-Or","year":"2015","unstructured":"Gan-Or Z, Dion PA, Rouleau GA. Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy. 2015;11(9):1443\u201357.","journal-title":"Autophagy"},{"issue":"2","key":"856_CR96","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3390\/ijms25021125","volume":"25","author":"A Longobardi","year":"2024","unstructured":"Longobardi A, Catania M, Geviti A, Salvi E, Vecchi ER, Bellini S, et al. Autophagy markers are altered in alzheimer\u2019s disease, dementia with lewy bodies and frontotemporal dementia. Int J Mol Sci. 2024;25(2):1125.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"856_CR97","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/NEN.0b013e318211c86a","volume":"70","author":"S Higashi","year":"2011","unstructured":"Higashi S, Moore DJ, Minegishi M, Kasanuki K, Fujishiro H, Kabuta T, et al. Localization of MAP1-LC3 in vulnerable neurons and lewy bodies in brains of patients with dementia with lewy bodies. J Neuropathology Experimental Neurol. 2011;70(4):264\u201380.","journal-title":"J Neuropathology Experimental Neurol"},{"issue":"7","key":"856_CR98","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","volume":"22","author":"SH Shahmoradian","year":"2019","unstructured":"Shahmoradian SH, Lewis AJ, Genoud C, Hench J, Moors TE, Navarro PP, et al. Lewy pathology in parkinson\u2019s disease consists of crowded organelles and lipid membranes. Nat Neurosci. 2019;22(7):1099\u2013109.","journal-title":"Nat Neurosci"},{"key":"856_CR99","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fnins.2020.00624","volume":"14","author":"S Mazzetti","year":"2020","unstructured":"Mazzetti S, De Leonardis M, Gagliardi G, Calogero AM, Basellini MJ, Madaschi L, et al. Phospho-HDAC6 gathers into protein aggregates in parkinson\u2019s disease and atypical parkinsonisms. Front Neurosci. 2020;14:624.","journal-title":"Front Neurosci"},{"issue":"10","key":"856_CR100","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/mds.29204","volume":"37","author":"P Lansbury","year":"2022","unstructured":"Lansbury P. The sphingolipids clearly play a role in parkinson\u2019s disease, but nature has made it complicated. Mov Disord. 2022;37(10):1985\u20139.","journal-title":"Mov Disord"},{"issue":"4","key":"856_CR101","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00401-021-02266-7","volume":"141","author":"D Erskine","year":"2021","unstructured":"Erskine D, Koss D, Korolchuk VI, Outeiro TF, Attems J, McKeith I. Lipids, lysosomes and mitochondria: insights into lewy body formation from rare Monogenic disorders. Acta Neuropathol. 2021;141(4):511\u201326.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"856_CR102","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1038\/cdd.2017.128","volume":"24","author":"J Knupp","year":"2017","unstructured":"Knupp J, Martinez-Montanes F, Van Den Bergh F, Cottier S, Schneiter R, Beard D, et al. Sphingolipid accumulation causes mitochondrial dysregulation and cell death. Cell Death Differ. 2017;24(12):2044\u201353.","journal-title":"Cell Death Differ"},{"issue":"1","key":"856_CR103","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/hmg\/ddm289","volume":"17","author":"C Settembre","year":"2008","unstructured":"Settembre C, Fraldi A, Jahreiss L, Spampanato C, Venturi C, Medina D, et al. A block of autophagy in lysosomal storage disorders. Hum Mol Genet. 2008;17(1):119\u201329.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"856_CR104","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of prasinezumab in early-stage parkinson\u2019s disease. N Engl J Med. 2022;387(5):421\u201332.","journal-title":"N Engl J Med"},{"key":"856_CR105","doi-asserted-by":"publisher","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB et al. Prasinezumab slows motor progression in rapidly progressing early-stage parkinson\u2019s disease. Nat Med. 2024;30(4):1096\u20131103. https:\/\/doi.org\/10.1038\/s41591-024-02886-y","DOI":"10.1038\/s41591-024-02886-y"},{"key":"856_CR106","doi-asserted-by":"publisher","unstructured":"McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A et al. Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update. J Parkinson\u2019s Disease. 2024. https:\/\/doi.org\/10.3233\/JPD-240272","DOI":"10.3233\/JPD-240272"},{"issue":"7","key":"856_CR107","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine alzheimer\u2019s disease therapeutics. Drugs. 2023;83(7):569\u201376.","journal-title":"Drugs"},{"issue":"1","key":"856_CR108","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"856_CR109","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic alzheimer disease: the Trailblazer-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512\u201327.","journal-title":"JAMA"},{"issue":"1","key":"856_CR110","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1038\/s41467-023-43514-6","volume":"14","author":"H Berven","year":"2023","unstructured":"Berven H, Kverneng S, Sheard E, S\u00f8gnen M, Af Geijerstam SA, Haugarvoll K, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in parkinson\u2019s disease. Nat Commun. 2023;14(1):7793.","journal-title":"Nat Commun"},{"issue":"2","key":"856_CR111","doi-asserted-by":"publisher","first-page":"e209570","DOI":"10.1212\/WNL.0000000000209570","volume":"103","author":"A Hart","year":"2024","unstructured":"Hart A, Aldridge G, Zhang Q, Narayanan NS, Simmering JE. Association of terazosin, doxazosin, or Alfuzosin use and risk of dementia with lewy bodies in men. Neurology. 2024;103(2):e209570.","journal-title":"Neurology"},{"issue":"12","key":"856_CR112","doi-asserted-by":"publisher","first-page":"168144","DOI":"10.1016\/j.jmb.2023.168144","volume":"435","author":"C Themistokleous","year":"2023","unstructured":"Themistokleous C, Bagnoli E, Parulekar R, Muqit MM. Role of autophagy pathway in parkinson\u2019s disease and related genetic neurological disorders. J Mol Biol. 2023;435(12):168144.","journal-title":"J Mol Biol"},{"key":"856_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-017-0154-3","volume":"12","author":"TE Moors","year":"2017","unstructured":"Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin M-C, et al. Therapeutic potential of autophagy-enhancing agents in parkinson\u2019s disease. Mol Neurodegeneration. 2017;12:1\u201318.","journal-title":"Mol Neurodegeneration"},{"issue":"724","key":"856_CR114","doi-asserted-by":"publisher","first-page":"eadd0499","DOI":"10.1126\/scitranslmed.add0499","volume":"15","author":"MR Khan","year":"2023","unstructured":"Khan MR, Yin X, Kang S-U, Mitra J, Wang H, Ryu T, et al. Enhanced mTORC1 signaling and protein synthesis in pathologic \u03b1-synuclein cellular and animal models of parkinson\u2019s disease. Sci Transl Med. 2023;15(724):eadd0499.","journal-title":"Sci Transl Med"},{"issue":"3","key":"856_CR115","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","volume":"30","author":"C Malagelada","year":"2010","unstructured":"Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA. Rapamycin protects against neuron death in in vitro AndIn vivo models of parkinson\u2019s disease. J Neurosci. 2010;30(3):1166\u201375.","journal-title":"J Neurosci"},{"issue":"5","key":"856_CR116","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41419-024-06770-y","volume":"15","author":"T Kataura","year":"2024","unstructured":"Kataura T, Sedlackova L, Sun C, Kocak G, Wilson N, Banks P, et al. Targeting the autophagy-NAD axis protects against cell death in Niemann-Pick type C1 disease models. Cell Death Dis. 2024;15(5):382.","journal-title":"Cell Death Dis"},{"key":"856_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2017.07.009","volume":"43","author":"LJ Vergouw","year":"2017","unstructured":"Vergouw LJ, van Steenoven I, van de Berg WD, Teunissen CE, van Swieten JC, Bonifati V, et al. An update on the genetics of dementia with lewy bodies. Parkinsonism Relat Disord. 2017;43:1\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"856_CR118","doi-asserted-by":"publisher","first-page":"1163184","DOI":"10.3389\/fnagi.2023.1163184","volume":"15","author":"LJ Chwiszczuk","year":"2023","unstructured":"Chwiszczuk LJ, Breitve MH, Kirsebom B-EB, Selnes P, Fl\u00f8vig JC, Knapskog A-B, et al. The ANeED study\u2013ambroxol in new and early dementia with lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial. Front Aging Neurosci. 2023;15:1163184.","journal-title":"Front Aging Neurosci"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00856-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:04:09Z","timestamp":1781604249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-025-00856-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":118,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00856-7","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}